{"nctId":"NCT01476787","briefTitle":"Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma","startDateStruct":{"date":"2011-12-29","type":"ACTUAL"},"conditions":["Follicular Lymphoma"],"count":1030,"armGroups":[{"label":"Lenalidomide + Rituximab","type":"EXPERIMENTAL","interventionNames":["Drug: Rituximab","Drug: Lenalidomide"]},{"label":"Control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rituximab-CHOP","Drug: Rituximab-CVP","Drug: Rituximab-Bendamustine"]}],"interventions":[{"name":"Rituximab","otherNames":[]},{"name":"Lenalidomide","otherNames":["Revlimid"]},{"name":"Rituximab-CHOP","otherNames":[]},{"name":"Rituximab-CVP","otherNames":[]},{"name":"Rituximab-Bendamustine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed follicular lymphoma grade 1, 2 or 3a, Stage II-IV\n* Have no prior systemic treatment for lymphoma\n* Symptomatic follicular lymphoma requiring treatment.\n* Age ≥18 years\n* Eastern Cooperative oncology group performance status 0-2\n* Willing to follow pregnancy precautions\n\nExclusion Criteria:\n\n* Clinical evidence of transformed lymphoma or Grade 3b follicular lymphoma.\n* Major surgery (excluding lymph node biopsy) within 28 days prior to signing informed consent.\n* Known seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)\n* Known sensitivity or allergy to murine products.\n* Presence or history of central nervous system involvement by lymphoma\n* At high risk for a venous thromboembolic event (VTE) and not willing to take VTE prophylaxis\n* Any of the following laboratory abnormalities:\n* serum aspartate transaminase or alanine transaminase \\> 3x upper limit of normal (ULN), except in patients with documented liver involvement by lymphoma\n* total bilirubin \\> 2.0 mg/dl (34 µmol/L) except in cases of Gilberts Syndrome and documented liver or pancreatic involvement by lymphoma\n* creatinine clearance of \\< 30 mL/min","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review","description":"The Complete Response Rate (CR/CRu) is the percentage of participants who achieve complete response (CR/CRu) at 120 weeks as assessed per Independent Central Review.\n\n* Complete Response (CR): Disappearance of all evidence of disease.\n* Complete Response Unconfirmed (CRu): Disappearance of all disease with the exception of residual lymph nodes that are 1.5 cm or less in greatest transverse diameter and/or indeterminate bone marrow findings.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"53.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression-free Survival (PFS)","description":"Progression-free survival (PFS) is defined as the time from randomization into the study to the first observation of documented disease progression or death due to any cause.\n\nProgressive Disease (PD) is characterized by any of the following:\n\n* An increase of at least 50% in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal lymph node(s) or other disease sites.\n* The appearance of any new lesion during or after treatment.\n* An increase of at least 50% in the longest diameter of a previously identified node that was 1 cm or more in its short axis.\n* An increase of at least 50% in the size of other lesions (e.g., splenomegaly, hepatomegaly).\n\nBased on Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120.2","spread":null},{"groupId":"OG001","value":"123.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response Rate (CR) at 120 Weeks Per Independent Central Review","description":"The Complete Response Rate (CR) is the percentage of participants who achieve confirmed complete response (CR) at 120 weeks as assessed per Independent Central Review.\n\n\\- Complete Response (CR): Disappearance of all evidence of disease.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"32.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival (EFS)","description":"Event Free Survival (EFS) is defined as the time a participant remains free from certain negative events (disease progression, relapse, initiation of a new anti-lymphoma treatment, or death) between the date of randomization to the date of first documented progression, relapse, and initiation of a new anti-lymphoma treatment or death by any cause. Responding participants and those lost to follow up were censored at their last tumor assessment date.\n\nProgressive Disease (PD) is characterized by any of the following:\n\n* An increase of at least 50% in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal lymph node(s) or other disease sites.\n* The appearance of any new lesion during or after treatment.\n* An increase of at least 50% in the longest diameter of a previously identified node that was 1 cm or more in its short axis.\n* An increase of at least 50% in the size of other lesions (e.g., splenomegaly, hepatomegaly).\n\nBased on Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130.6","spread":null},{"groupId":"OG001","value":"132.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) is defined as the median length of time a participant stays alive from randomization. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who withdrew consent for the study were considered censored at the time of withdrawal. Participants who completed the study and were still alive at the time of the clinical data cut-off date were censored. All participants who were lost to follow-up prior to the clinical data cut-off date were also considered censored at the time of last contact. Based on Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Next Anti-Lymphoma Treatment (TTNLT)","description":"Time to Next Lymphoma Treatment (TTNLT) was measured from the date of randomization to the date of the first documented administration of any new anti-lymphoma treatment (such as chemotherapy, radiotherapy, radio-immunotherapy, or immunotherapy). Participants who continued to respond to treatment or who were lost to follow-up were considered censored on their last visit date. Participants who died (due to any cause) before receiving a new anti-lymphoma treatment were included in the statistical analysis, with death being counted as an event. Based on Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":181,"n":507},"commonTop":["NEUTROPENIA","CONSTIPATION","NAUSEA","ASTHENIA","DIARRHOEA"]}}}